EUROPEAN RENAL ASSOCIATION - EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION
Services
How to use the platform
Build a poster
MANAGE ORDERS
FAQs
Contact
HOMEPAGE
Virtual Poster Gallery
PrintingOnline for Collection on-site
Accredited Training
DOI - Digital Object Identifier
What is PosterSessionOnline?
How to send your poster
How to visit the Virtual Poster Gallery
How to build a poster
How to reduce a poster to less than 2 Mb
PosterSessionOnline Image Editor
How to build a poster with our templates
How to work with a template
Templates and instructions
Discussion forum -
49th ERA-EDTA Congress
Topic -
Clinical Nephrology - Lab methods and other markers
If you are already registered in PosterSessionOnline, enter your e-mail and click on LOGIN. Otherwise click on REGISTER.
Poster:
272
Visits:
647
Title:
PROCALCITONIN IS NOT SUPERIOR TO C-REACTIVE PROTEIN AS A MARKER OF INFECTION IN PATIENTS WITH CHRONIC KIDNEY DISEASE
Authors:
Ji Hyeon Park ,
Centre:
Samsung Medical Center
You must be registered to reply or comment.
PROCALCITONIN IS NOT SUPERIOR TO C-REACTIVE PROTEIN AS A MARKER OF INFECTION IN PATIENTS WITH CHRONIC KIDNEY DISEASE
Ji Hyeon Park
Thread initiator
Subspeciality
Reg:
5/7/2012 3:34:00 PM
Comment# 1
I invite healthcare professionals to open debate around the issues raised in my poster, both those relating to research and to clinical practice.
Comment added on 5/7/2012 3:34:00 PM
You must be registered to reply or comment.
Most viewed poster for this congress
Poster:
424
Visits:
2775
Title:
Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Glomerulonephritides: an Immunohystochemical expression analysis
Authors:
Giuseppe Coppolino ,
Centre:
Chair of Nephrology, University Magna Graecia of Catanzaro, Catanzaro, Italy
Poster most viewed in this topic
Poster:
51
Visits:
1513
Title:
A NEW MARKER IN NEPHROLOGY: THE APELIN
Authors:
Antonio Lacquaniti , Donato V, Fazio MR, Lucisano S, Lupica R, Cernaro V, Trimboli D, Buemi M.
Centre:
University of Messina
View Poster Gallery
Back to congress home
Other Congresses
About us
|
Terms and Conditions
|
Special Access